Trade Alerts

Mark Your Calendar: This Biotech Stock Could Surge Next Week

A single positive or negative announcement from the US Food and Drug Administration (FDA) can send shares of a biotech firm soaring.  

On February 28th, the U.S. FDA approved Reata Pharmeceuticals’ (RETA) lead candidate Skyclarys for treating patients with an inherited neuromuscular disease called Friedreich’s ataxia. 

The next day, Reata’s share price skyrocketed 199% to around $93, and its trading volume rose to 15x the average of the previous 90 days.

This is just one recent example of how explosive biotech stocks can be for patient, risk-tolerant investors willing to wait for the next big headline.

The rewards in biotech can change the game completely, which is why our team scours industry news looking for potential catalysts. And boy, do we have a story for you…

We’ve got our finger on one name that’s up for priority review by the FDA next week. We can’t say whether or not this company’s stock will surge on FDA approval in the coming days, but we wanted to share the details behind this potential millionaire-minting catalyst with you first… 

Verrica Pharmaceuticals Inc (VRCA)

Dermatology therapeutics company Verrica Pharmaceuticals’ lead product candidate, VP-102, is up for priority review by the FDA on Monday, July 23rd. VP-102 is in development to treat molluscum, common warts, and external genital warts, three of the most significant unmet needs in medical dermatology. 

VRCA’s share price is up 13% this week, 25% over the past month, and a whopping 163% this year. Will the stock surge following the FDA’s decision? We’ll have to wait and see. 

Other potential catalysts may come later this year as a result of the company’s recent partnership with Lytix Biopharma AS to develop and commercialize VP- 315 (formerly LTX-315 and VP-LTX-315) for dermatologic oncology conditions. 

The analyst community is increasingly enthusiastic about the stock. As it stands now, 5 of the six analysts offering recommendations say to Buy VRCA, with only one recommending to Hold. There are no Sell recommendations for the stock. A median price target of $11 implies a nearly 50% upside for the stock over the next 12 months. 

[stock_market_widget type=”accordion” template=”extended” color=”#5679FF” assets=”VRCA” start_expanded=”true” display_currency_symbol=”true” api=”yf”]

Is CTRA the Best Natural Gas Stock?

There very well may be a bullish market ahead for natural gas stocks, and analysts most definitely see it… 

Enter Coterra Energy (CTRA), a formidable player in the natural gas realm where vast reserves, cost-effective operations, and strong financial standing come together to offer up a confident performer. 

Coterra masterfully distributes its free cash flow to shareholders through a mix of regular dividends, buybacks, and occasional special dividends. CTRA’s performance history is also a sign of reliability. 

Coterra Energy will attract any income-focused investors who enjoy high future returns… 

Coterra Energy (CTRA) is one of the strongest choices in the energy sector right now. CTRA stands out as a top player due to its large reserves and solid balance sheet, making it a reliable income play. With a market cap of $21 billion, CTRA is among the biggest players in the industry, primarily generating revenue from natural gas sales, supplemented by oil and NGLs (natural gas liquids). 

CTRA‘s reserves are expected to last between 15 and 20 years, and it continues to explore new discoveries to replenish its inventory. Additionally, CTRA benefits from strong price realization, capturing around 100% of the WTI price and approximately 90% of natural gas in the Marcellus basin. With plans to reduce activity 

in the Marcellus and redirect resources to the promising Permian and Anadarko basins, this can contribute to CTRA’s projected oil production growth of 5% per year without increasing capital spending

By successfully maintaining healthy business metrics, CTRA is in an excellent position to return cash to shareholders. It offers a 7.94% annual dividend yield with a $0.20 per share quarterly payout. Moreover, CTRA repurchased 11 million shares totaling $268 million, representing 76% of the free cash flow returned to shareholders. It has also done a hell of a consistent job of beating analysts’ earnings projections. 

Most recently, CTRA beat EPS and revenue by margins of 24.11% and 13.09%, respectively. CTRA reported EPS of $0.87 per share vs. $0.70 per share as expected and revenue of $1.78 billion vs. $1.57 billion as expected. CTRA also boasts significant earnings beats for all of fiscal year 2022

For the present quarter, CTRA is projected to report $1.3 billion in sales at $0.37 per share. It is currently up by 9.28% year-to-date and trades around the bottom of its existing 52-week range, which leaves room for growth. CTRA has a volatility-safe beta score of 0.27 and a 10-day average trading volume of 6.54 million shares. As assigned by analysts, CTRA has a median price target of $29, with a high of $39 and a low of $25, giving it an upside potential of more than 45% of its current price. 

Considering its strategic buybacks and dividends, the company is clearly committed to its shareholders, and given the positive outlook on natural gas prices and CTRA‘s strengths as a top-tier player, it is a compelling buy for investors with a bullish view of the energy sector. 

[stock_market_widget type=”accordion” template=”extended” color=”#5679FF” assets=”CTRA” start_expanded=”true” display_currency_symbol=”true” api=”yf”]

Two Stocks to Buy and One to Sell Next Week

Stocks rallied to close the week after a smaller-than-expected rise in consumer prices for October fueled hopes of cooling inflation. The S&P 500 closed the week more than 5% higher, logging its best weekly performance since June. Meanwhile, the Dow added 4%, and the Nasdaq Composite stacked on around 8%.  

Since the U.S. government officially introduced the first-ever tax credit for energy storage projects, the industry has had remarkable positive business developments. Our first buy recommendation for today is a company gaining traction as plans for much-needed upgrades to the nation’s aging power grid unfold.  

NextEra Energy (NEE) is the world’s largest producer of solar and wind energy. They’re owners of Florida Power & Light and some other utilities and businesses that do wholesale energy. They’re also the sponsor of NextEra Energy Partners, which is primarily renewable energy focused. Renewables are a big part of NextEra’s business. NextEra has emerged as the world’s most valuable utility, largely by betting on utilities, especially wind.  

NextEra had about 30 gigawatts of wind and solar farms at the end of last year, enough to power 17 million homes. And it’s expanding significantly, with contracts to add another 10 gigawatts of renewables. 

For decades, NextEra Energy has been reducing emissions through developing renewable energy and modernization of its generation fleet. The company’s goal is to reduce the CO2 emissions rate by 67% by 2025 from a 2005 baseline. This equates to a nearly 40% reduction in absolute CO2 emissions, despite the company’s total expected electricity production almost doubling from 2005 to 2025. Working toward this goal, as of year-end 2021, NextEra has reduced its CO2 rate by 62.2%  and the absolute CO2 tons by 20% while their generation increased by 67.5%. That’s pretty impressive.  

NextEra Energy has more energy storage capacity than any other company in the U.S., With more than 180 MW of battery energy storage systems in operation. The company leads the industry with storage innovations such as its Babcock Ranch Solar Energy Center – the largest combined solar-plus-storage facility in the country. This cutting-edge project incorporates a 10-MW battery storage project into the operations of a 74.5-MW solar power plant.

NextEra has a solid track record of success. Between 2006 and 2021, their adjusted earnings per share grew at a compound annual growth rate of 8.4%, while dividends grew at a compound annual growth rate of 9.4%, that’s incredible growth over 15 years. Over the past five years, the stock is up 137% on a total return basis. That type of performance is not typical for a utility company which indicates that NextEra truly is an outlier in the industry. 

The undisputed global leader when it comes to identity security, CyberArk (CYBR), has been gaining attention on Wall Street. The stock is up 26% over the past six months and could continue to gain heading into 2023. Regardless of any short-term earnings volatility, the potential for long-term, steady growth is too great to ignore.  

CyberArk’s innovations occur across its self-hosted solutions and expanding SaaS portfolio of privileged access management, secrets management, and cloud privilege security offerings, helping its customers enable “Zero Trust” by enforcing the least privilege. Under the framework of its Zero Trust approach, its teams can focus on identifying, isolating, and stopping threats from compromising identities and gaining privilege before they can do harm.

The Israel-based company was recently named a leader in the Gartner Magic Quadrant for Privileged Access Management for 2021. It was positioned both highest in the ability to execute and furthest in completeness of vision for the fourth time in a row. It comes as no surprise the business has been attracting customers to its subscription-based services, which means tremendously reliable cash flow, a good sign for anyone eyeing the small-cap.  

For its third quarter, CyberArk reported a 133% growth acceleration from the previous year’s quarter of the subscription portion of its annual recurring revenue (ARR) to $255 million. Total ARR came in at $465 million, with growth Accelerating to 48%. Management also increased the full-year 2022 ARR Guidance Range to  $589-$601 million, up from a prior estimate of $583.5-$598.5 million.

Over the past two years, the dramatic shift from brick-and-mortar shopping to e-commerce has been a tremendous obstacle for investors in malls and shopping centers. The demise of cornerstones like Sears and JCPenny hastened the decline as shopping malls are now left without anchor tenants.   Recent data suggests that 25% of America’s 1,000 malls will be closed in the next 3-5 years.  

Leading shopping mall REIT Simon Property (SPG) is struggling to pivot amid the inevitable decline of its core asset group. The REIT has been aggressive in diversifying into outlets and foreign real estate, which may help to hedge against increasingly substantial losses from their shopping mall category. But given current inflation and the possibility of an economic slowdown, both shoppers and retailers may be in a tight spot this holiday season which will inevitably weigh heavily on SPG.  

Investors choose REIT stocks because of their income-producing abilities and yields. The fact that SPG is concentrated in brick-and-mortar retail is tangential to its income feature. Anyone looking for the reliable income that real estate and mortgage investments can bring would be wise to steer clear of Simon Property for now.  

Read Next – Get Out of U.S. Banks Immediately

A Wall Street legend has warned 8.4 million Americans to prepare immediately.

A historic financial reset in 2023 could cause a run on the banks unlike anything we’ve seen in our country’s history,” he says.

Marc Chaikin has already appeared on 30 different TV networks to share his warning.

Even CNBC’s Jim Cramer has taken notice.

But few people realize this could actually happen on U.S. soil.

Or what a sizable impact it could have on your wealth, especially if you have large amounts of cash in the bank right now.

Chaikin is best known for predicting the COVID-19 crash, the 2022 sell-off, and the overnight collapse of Priceline.com during a CNBC debate.

In his 50-year Wall Street career, he worked with hedge funds run by billionaires Paul Tudor Jones and George Soros.

But today, he is now urging you to move your money out of cash and popular stocks and into a new vehicle 50 years in the making.

“This is by far the best way to protect and grow your money in what will surely be a very difficult transition for most people,” Chaikin says.

Click here for the full story, and his free recommendation.

Three Mid-Cap Tech Stocks to Snap Up Before It’s Too Late

With the Nasdaq solidly in a bear market, most market participants are busy talking about the steep losses tech names have suffered. But in the long term, the technology sector will be a force to reckon with in the market, and if history repeats itself, stocks from the technology sector could start their path to recovery sooner than other stocks. Following the dot-com bubble and the financial crisis of 2008, the tech-heavy Nasdaq Composite hit its trough long before the S&P 500. 

This go around, for innovation-focused investors, the potential of some mid-cap tech stocks (stocks with a market cap. that is > $2 billion and < $10 billion) should not be ignored. While small-cap stocks are often fast-growing but volatile, and large-cap stocks tend to be slow growing and relatively stable, the best mid-caps tend to fall in between: less volatile than fast-moving small caps but with more growth potential than mammoth large-cap companies. Top-ranked mid-cap stocks have a high potential to enhance their profitability, productivity, and market share.

Our research team has a few recommendations for mid-cap tech stocks poised to take off when the technology sector regains traction.  

DXC Technology Co. (DXC) is a provider of information technology services and products targeting IT modernization, including both on-premises and cloud services, as well as data-driven operations and workplace modernization. The company serves 6,000 customers globally across the private and public sectors and has a market cap of $6.55 billion.

For its second quarter, DXC Technology reported $3.57 billion in revenue, down 11.5% year-over-year and slightly higher than the $3.55 billion Wall Street was expecting. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.73.   

“I am pleased with our second quarter results, where we delivered organic revenue, margin, and EPS at the top end of our guidance range. This is the kind of strong performance that we are accustomed to, as our revenue performance is one of the best results we have delivered, and our margins are clearly benefiting from our cost optimization program. All of this gives us confidence that we have built a quality company that is well-positioned to achieve our short-term and long-term goals,” commented  Mike Salvino, DXC Chairman, President, and CEO.

DXC’s share price has fallen 15% in 2022, leaving them priced at only around eight times this year’s projected earnings. Short-term, prolonged market weakness could continue to weigh heavily on the stock, but those with a longer-term outlook will likely appreciate a deeper pull-back as an opportunity to get in at a better price.  

Founded in 2001, Canadian Solar Inc. (CSIQ) is a leading manufacturer of solar photovoltaic modules and a provider of solar energy solutions. CSIQ has delivered around 52 GW of solar modules to thousands of customers in more than 150 countries through the end of 2021, reaching approximately 13 million households. Canadian Solar derives roughly 47% of its revenue from Asia, 35% from the Americas, and 18% from Europe and everywhere else.

Canadian Solar is one of the most bankable companies in the solar and renewable energy industry, having been publicly listed on the NASDAQ since 2006. With a market cap of $2.8 billion, the company has the potential to advance based on its continued business growth, favorable earnings, and revenue outlook.

Benefitting from renewed interest in renewable energy solutions, Canadian Solar posted revenue of $2.31 billion in Q2 of this year, up nearly 62% from the year-ago quarter. CSIQ is up 19% year to date, while the Nasdaq index is down 29% during the same period, making Canadian Solar intriguing on a relative level. Moreover, the share price remains 39% below its February 2021 peak, and now may be a good time to buy before the next leg up.  

Online security is a young, quickly evolving industry. Competition is heavy in the space, and demand continues to grow faster in both volume and complexity. Not all companies from the burgeoning subsector are set to last. The undisputed global leader when it comes to identity security, CyberArk (CYBR), has been gaining attention on Wall Street. The stock is up 26% over the past six months and could continue to gain heading into 2023. Regardless of any short-term earnings volatility, the potential for long-term, steady growth is too great to ignore.  

CyberArk’s innovations occur across its self-hosted solutions and expanding SaaS portfolio of privileged access management, secrets management, and cloud privilege security offerings, helping its customers enable “Zero Trust” by enforcing least privilege. Under the framework of its Zero Trust approach, its teams can focus on identifying, isolating, and stopping threats from compromising identities and gaining privilege before they can do harm.

The Israel-based company was recently named a leader in the Gartner Magic Quadrant for Privileged Access Management for 2021. It was positioned both highest in the ability to execute and furthest in completeness of vision for the fourth time in a row. It comes as no surprise the business has been attracting customers to its subscription-based services, which means tremendously reliable cash flow, a good sign for anyone eyeing the small-cap.  

For its third quarter, CyberArk reported a 133% growth acceleration from the previous year’s quarter of the subscription portion of its annual recurring revenue (ARR) to $255 million. Total ARR came in at $465 million, with growth accelerating to 48%. Management also increased the full-year 2022 ARR Guidance Range to  $589-$601 million, up from a prior estimate of $583.5-$598.5 million. With a market cap of $6.21 billion, CYBR is one of the top choices of mid-cap cybersecurity stocks available.

Three Stocks to Watch for the Week of November 28th

The major indices inched higher for the holiday-shortened week as FOMC meeting minutes fueled optimism that the Fed may soon begin to ramp down from the historically significant 0.75% rate hikes it has implemented in the past four consecutive meetings. A “substantial majority of participants” thought that a slowdown “would likely soon be appropriate,” according to the minutes from the Fed’s mid-November meeting, released Wednesday. The Dow gained 1.7%, the Nasdaq rose 0.7%, and the S&P 500 climbed 1.5% for the week, finishing above the 4,000 level for the first time in two months. As of Friday’s close, the S&P 500 has risen 12% from its recent mid-October low.  

This week, the labor market will be in the spotlight with October’s Job Openings and Labor Turnover Survey (JOLTS) and ADP’s National Employment Report for November due for Release on Wednesday. Then on Friday, the Bureau of Labor Statistics will release its nonfarm payrolls report for November. Market watchers will get clarity on how inflation is affecting U.S. consumer spending with PCE data due out on Thursday. We’ll also find out if the U.S. housing market continued to cool in September with the release of S&P Global’s Case-Shiller National Home Price Index, slated for Tuesday. 

Our team has three stock recommendations for the week ahead, the first of which may not come as a surprise, considering its strong performance this year. What is surprising is that this historically recession-resistant ticker is still so cheap. 

It should be no surprise that the defense giant  Lockheed Martin (LMT) has outperformed the market this year. There are obvious geopolitical implications with the war in Ukraine. When Russia decided to invade its neighbor, both U.S. and European forces rushed in to help Ukraine. It may be some time before LMT stock pops again, as it did at the onset of Russia’s invasion of Ukraine. However, its order books are likely to improve due to rising defense budgets in the U.S. and abroad. Along with Lockheed providing support to Ukrainian resistance fighters, the looming uncertainties in Russia could lead to massive economic problems and gaps in power in the former Soviet Union-controlled areas. 

Given the recession-proof nature of defense contracting, Lockheed Martin should continue reporting positive results and rewarding shareholders through its quarterly 2.7% forward yield. In other words, LMT will likely stand firm even if the market dives again. The company runs a P/E ratio of 24 times, below the sector median of 28.3 times. As well, LMT features excellent longer-term growth and profitability metrics.

Global healthcare leader Eli Lilly And Company (LLY) has been creating high-quality medicines for over a century. The drug firm focuses on endocrinology, oncology, neuroscience, and immunology. Key products include Trulicity, Jardiance, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Verzenio and Alimta for cancer.  

In September, Lilly’s immunology drug Olumiant received emergency use authorization from the FDA to treat hospitalized COVID-19 patients. Moreover, the drug has produced impressive results from phase 3 trials examining Olumiant’s efficacy as a hair loss treatment.   

The mega-cap pharmaceutical giant’s pipeline is locked and loaded with promising advancements, which means plenty of potential upcoming opportunities for investors to benefit from. In the first half of 2021, Lilly increased research and development spending for its up-and-coming treatment for diabetes Tirzepatide by 21% to $3.36 billion. The drug is currently in phase three trials and has already proven to be more effective than competitors.

Berenberg Analyst Herry Holford recently upgraded Eli Lilly to Buy from Hold and raised the price target from $240 to $270. “Pipeline progress has effectively locked in Eli Lilly’s long-term sales growth, which now stands at 10% annually through 2030 versus a peer average of 4%,” Holford tells investors in a research note. The analyst says a “confluence of catalysts, superior growth, and superior returns” on Research and development, compounded by the recent pullback in the stock, prompts a revisit to the investment thesis.  

The board of directors at Eli Lilly declared a fourth-quarter dividend of $0.85. LLY’s dividend payout for the year is set for the low 40% range, which should allow for robust future dividend growth.

A strong pipeline and a stable dividend make Eli Lilly an attractive consideration. The pros on Wall Street also think so. Among 17 polled analysts, 12 say to Buy LLY, 4 call it a Hold, and only 1 rates the stock a Sell. A median 12-month price target of $279 represents a 12.6% increase from its current price.

Pioneer Natural Resources Company (PXD) has long viewed sustainability as a balance of economic growth, environmental stewardship, and social responsibility. Its emphasis is on developing natural resources in a manner that protects surrounding communities and preserves the environment.

In the wake of the pandemic, when energy prices were low, PXD struck an almost perfectly timed agreement to buy fellow Permian Basin producer Parsley Energy for $4.5 billion. If you’re wondering how PXD managed to finance that transaction, the answer lies in the fact that it was an all-stock deal that ensured Pioneer didn’t have a new giant debt load hanging over its head. The fact that Parsley operated primarily in the same region of West Texas, where Pioneer had both expertise and existing staff, has paid off over time.   

That deal was a coup for Pioneer shareholders, built on the fact it was large and well-capitalized at a time when stressed and debt-reliant shale plays were looking for a white knight. On top of that acquisition, PXD also boosted its dividend by 25% at the start of the year as further evidence of its strong balance sheet.

Investors can look forward to upcoming tailwinds, including Pioneer’s recently announced partnership with the world’s largest renewable energy producer, NextEraEnergy (NEE), to develop a 140-megawatt wind generation facility on Pioneer-owned land. The project will supply the company’s Permian Basin operations with low-cost, renewable power and is expected to be operational next year.  

In the third quarter, revenue was up 22% YOY to $6.09 billion, smashing the consensus estimate of 4.57 billion. The company reported earnings of $7.48 per share, beating consensus expectations of $7.27 per share. So far, in 2022, the company has rewarded its investors handsomely with $20.73 per share through its generous 10.78% cash dividend. Even after gaining 30% this year, Pioneer shares likely still have valuation upside in addition to their tremendous dividend income potential.   

Popular Posts

My Favorites

Three Value Stocks to Buy Now

0
The past year produced a performance chasm between value and growth equities, with value recapturing the lead following a strong run for growth in...